AI-generated analysis. Always verify with the original filing.
Spyre Therapeutics, Inc. issued a press release via Exhibit 99.1 regarding its financial results. The filing is furnished under Item 2.02 and includes Item 9.01 for financial statements and exhibits.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “E
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release issued by Spyre Therapeutics, Inc. regarding its financial results